Yellowbird Diagnostics Closes an Oversubscribed Funding Round

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Yellowbird Diagnostics, specializing in biomedical imaging solutions across commonly used clinical imaging technologies, recently announced closing an oversubscribed funding round. With this funding, Yellowbird aims to launch first-in-human scans and a Phase 1 clinical trial for their lead product, NeuCaVis, unlocking the full potential of PET imaging.

Yellowbird Diagnostics is an OBIO® member, alumnus of the CAAP® program, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing
Next

Lumira Ventures and Terry Fox Foundation Partner to Launch The Cancer Breakthrough Fund